Home > Low early PASI response could predict favourable outcomes for psoriasis patients on biologics

Low early PASI response could predict favourable outcomes for psoriasis patients on biologics

Presented By
Dr Nikolai Dyrberg, University of Copenhagen, Denmark
Conference
EADV 2020
Greater treatment compliance and fewer flare-ups were seen in bio-naïve patients with psoriasis treated with biologic therapy who had an early Psoriasis Area and Severity Index (PASI) score of ≤2. Dr Nikolai Dyrberg (University of Copenhagen, Denmark) presented the findings of a Danish nationwide study that followed 1,684 patients with psoriasis receiving biologic therapy for the first time [1]. Median response time was 112 days. At baseline, 746 participants had a PASI of 0; 485 had a PASI between 0 and ≤2; 246 had a PASI >2 but ≤4; and 207 had a PASI >4. Defining a flare-up as any increase of their PASI score by ≥3, 42.8% of patients experienced flare-ups. However, patients with a lower PASI score during the first 6 months of treatment experienced longer flare-free periods. These outcomes were independent of drug, sex, age, weight, and use of methotrexate. Dr Dyrberg’s team documented a more stable disease course, lower risk...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on